OOIR: Observatory of International Research

Papers

(The median citation count of Drug Metabolism Reviews is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
CYP24A1: the pivotal regulator of vitamin D homeostasis, pathophysiology in metabolic and genetic disease, and emerging target for precision medicine	55
Drug transporters in drug disposition – the year 2022 in review	41
New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments	38
Differential modulation of cytochrome P450 enzymes by arsenicals in non-human experimental models	27
Enantioselectivity in some physiological and pathophysiological roles of hydroxyeicosatetraenoic acids	23
An in-depth review of PPARγ modulators as anti-diabetes therapeutics	22
Phase II metabolism in xenobiotic biotransformation: general mechanisms and the underestimated role of microbial systems	20
A critical review of analytical tools for the detection of spironolactone and its metabolites	18
Mechanisms of intestinal pharmacokinetic natural product-drug interactions	18
Redox enzyme networks shaping cancer drug metabolism and therapeutic resistance	18
Multimolecular interactions from Chinese medicines activate nuclear receptor conformational changes: a potential strategy for anti-inflammatory therapy	17
Cytochrome P450-mediated carbon-carbon bond formation in drug metabolism	16
Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations	15
Metabolism of new drug modalities research advances – 2024 year in review	14
Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special population	13
Genetic determinants of paclitaxel-induced peripheral neuropathy: a review of current literature	12
Biopolymers as promising vehicles for drug delivery to the brain	12
Drug transporters in drug disposition – highlights from the year 2024	12
Biotransformation research advances—2025 year in review	11
Molecular insights into doxorubicin-induced cardiotoxicity and phytochemical-based cardioprotection: challenges and future strategies	11
Pharmacomicrobiomics in precision pharmacotherapy: bidirectional microbial-drug interactions as a key determinant of therapeutic response	11
Scaling factors to inform in vitro - in vivo extrapolation from preclinical and livestock animals: state o	10
Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice	10
Clinical pharmacokinetics of nebivolol: a systematic review	9
Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods	9

Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs	9
Advances in drug resistance of osteosarcoma caused by pregnane X receptor	8
Correction	8
In silico ADME and target prediction studies of Alogliptin as drug molecule	8
Biotransformation research advances – 2023 year in review	7
In-depth understanding of the structure-based reactive metabolite formation of organic functional groups	7
Correction	7
Aldehyde oxidase mediated drug metabolism: an underpredicted obstacle in drug discovery and development	7
Analytical techniques for methyldopa and metabolites: a comprehensive review	6
Metabolism of m -CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects	6
Simplified approaches to kinetic isotope effects in cytochrome P450-catalyzed reactions and relevance to deuterated drugs	6
Melatonin in cancer biology: pathways, derivatives, and the promise of targeted delivery	5
Pregnane X receptor (PXR/NR1I2): linking drug metabolism, bile acid detoxification, and cholesterol homeostasis	5
Relationship between blood–brain barrier changes and drug metabolism under high-altitude hypoxia: obstacle or opportunity for drug transport?	5
3D self-assembled nanocarriers for drug delivery	5
Physiological and pathophysiological roles of hepoxilins and their analogs	5
Relevance of reactive metabolites and covalent binding to drug candidate selection	5
Cytochrome P450-derived arachidonic acid metabolites as emerging therapeutic targets in menopause-associated cardiac hypertrophy	5
How gut microbiota modulate anesthetic drug response and perioperative outcomes	4
Bioactivation and reactivity research advances – 2025 year in review	4
Cutting-edge strategies and critical advancements in characterization and quantification of metabolites concerning translational metabolomics	4
Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms	4
Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic	4
Interaction of drugs with gut microbiota modulators	4
The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure	4
Population pharmacokinetics of levofloxacin: a systematic review	4